Last reviewed · How we verify
LPM6690176
At a glance
| Generic name | LPM6690176 |
|---|---|
| Also known as | LY01024 |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation (PHASE1, PHASE2)
- First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPM6690176 CI brief — competitive landscape report
- LPM6690176 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI